Avalo Therapeutics
AVTX
53 hedge funds and large institutions have $131M invested in Avalo Therapeutics in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 6 closing their positions.
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
16% more capital invested
Capital invested by funds: $113M → $131M (+$18.3M)
2% more funds holding
Funds holding: 52 → 53 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.06M |
| 2 |
Goldman Sachs
New York
|
+$549K |
| 3 |
MWM
Minot Wealth Management
Westwood,
Massachusetts
|
+$292K |
| 4 |
AC
Armistice Capital
New York
|
+$285K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$222K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.81M |
| 2 |
Two Sigma Investments
New York
|
-$278K |
| 3 |
SCM
Sio Capital Management
New York
|
-$250K |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
-$233K |
| 5 |
Renaissance Technologies
New York
|
-$222K |
AVTX Hedge Fund Activity: Q4 2020 in Review
53 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q4 2020, worth a combined $131M — up 16% from $113M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new AVTX positions and 6 closed out — a net gain of 1 holder — while 21 added to existing stakes and 11 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $1.06M. The largest seller was Opaleye Management, cutting an estimated $1.81M.
- 53 institutional investors held Avalo Therapeutics (AVTX) as of Q4 2020, up from 52 in Q3 2020.
- Funds reported $131M of Avalo Therapeutics stock for Q4 2020, up 16% quarter-over-quarter.
- 7 funds opened new Avalo Therapeutics positions in Q4 2020 and 6 closed out, a net change of +1 holder.
- The largest Avalo Therapeutics buyer in Q4 2020 was Nantahala Capital Management, an estimated $1.06M added.
- The largest Avalo Therapeutics seller in Q4 2020 was Opaleye Management, an estimated $1.81M sold.
Based on aggregated 13F filings for Q4 2020.